WEST LAFAYETTE, Ind., Jan. 26, 2016 /PRNewswire-iReach/ -- On Target Laboratories LLC closed out 2015 reaching new research milestones in the development of a groundbreaking method to illuminate previously hidden cancer cells during surgery.
Photo - http://photos.prnewswire.com/prnh/20160126/325953
In December, On Target Laboratories completed a 47-patient, multi-center Phase 2 study of OTL38 use for intra-operative imaging of Folate Receptor-alpha Positive Ovarian Cancer. Data is currently being analyzed and final results from this Phase 2 study will be submitted in early 2016.
In addition to studies in Ovarian Cancer, On Target Laboratories began an Investigator Sponsored Trial, testing OTL38 for intra-operative imaging in pituitary surgeries. The first two surgeries were performed in November, and the goal of the trial is to conduct approximately 20 pituitary surgeries by the first quarter of 2016. With positive results, OTL38 would quickly progress to a multi-center study.
About On Target Laboratories LLC
On Target Laboratories is in the business of discovering, developing and commercializing small molecules that, when conjugated with fluorescent dyes, target and illuminate specific cancerous cells and other diseased tissue. These conjugates can be used by doctors, including surgeons, worldwide to better diagnose and treat a wide range of diseases from cancer to inflammation-related disorders.
Media Contact:Elizabeth Estes, On Target Laboratories, LLC, 313-749-9323, media@ontargetlabs.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE On Target Laboratories LLC
